Table 4.
Incremental Cost-Effectiveness Ratios (ICER) as Function of Screening Stop Age in 1000 Individuals, with and Without Diabetes Diagnosis at age 50
| Population | Screening strategy | Difference in total medical cost as compared with no screening (in $1000) | QALY gained as compared with no screening | ICER ($ per QALY saved) | |
|---|---|---|---|---|---|
| # | Name | ||||
| With history of diabetes at baseline | 1 | No screening | 0 | 0.0 | -- |
| 2 | Screening is discontinued after age 50 | 655 | 105.5 | 6,209 | |
| 3 | Screening is discontinued after age 60 | 980 | 123.9 | 17,663 | |
| 4 | Screening is discontinued after age 70 | 1179 | 129.5 | 35,563 | |
| 5 | Screening is discontinued after age 80 | 1241 | 129.8 | 206,671 | |
| 6 | No stop age | 1268 | 129.9 | 270,005 | |
| Without history of diabetes at baseline | 1 | No screening | 0 | 0.0 | -- |
| 2 | Screening is discontinued after age 50 | -143 | 152.4 | -- | |
| 3 | Screening is discontinued after age 60 | 85 | 190.8 | 5,937 | |
| 4 | Screening is discontinued after age 70 | 245 | 206.0 | 10,526 | |
| 5 | Screening is discontinued after age 80 | 353 | 208.3 | 46,957 | |
| 6 | No stop age | 384 | 208.7 | 77,500 | |